We use cookies to understand how our site is used so we can improve it. Necessary cookies are always on. You can accept all, reject all, or choose what to allow. Learn more
Surgical RoboticsIt put the surgeons on the cap table.
Surgical Robotics
It put the surgeons on the cap table.
Curexo was a sleepy medical-device distributor with a near-zero-debt balance sheet and ₩187bn of cash. It has quietly turned itself into a surgical-robot platform OEM — CUVIS-joint and CUVIS-spine — taking on Stryker's Mako and Zimmer's ROSA not on scale but on an open platform the majors deliberately keep closed. FY2025 was its first clear profit after four loss years. Then, in April 2026, it handed convertible bonds to three named orthopedic surgeons. That is not a financing event. It is a tell about how this business actually grows.
A robot-assisted joint-replacement procedure. Curexo's CUVIS-joint drives the bone cut autonomously and works with any implant brand — the open architecture that the implant majors, who use the robot to lock surgeons into their own hardware, will not offer. That single design choice is the whole strategy.
For most of its life Curexo was the kind of company a diligence team skims and sets aside: a Korean medical-device distributor, reselling other people's knee implants and shuttling food ingredients between affiliated factories, sitting on a strangely large pile of cash and going nowhere in particular. That description is now wrong. Underneath the dull distributor was a second company being assembled — an asset-light surgical-robot platform OEM that owns the software, the regulatory approvals and the brand for CUVIS-joint and CUVIS-spine, and owns no factories at all. FY2025 was the year the disguise dropped: the first clearly profitable year after four straight losses, driven entirely by the robots.
The robot business has a peculiar economic shape that explains everything else. A surgical robot is not really sold once. The system goes into a hospital, and from then on it meters revenue — cutting tools, optical markers and arrays, fixation pins, service and maintenance, procedure after procedure. The installed base is the annuity, and the cumulative-procedure count is the meter reading. Curexo has put robots into roughly 100 hospitals across nine-plus countries, and those machines have now performed about 43,000 procedures. That number, not last quarter's revenue, is the asset.
What makes Curexo more than a small fast-follower is one design decision the giants will not copy. Stryker's Mako, Zimmer's ROSA, J&J's VELYS — each is a closed platform, engineered so that buying the robot means buying that maker's implants for the life of the machine. The robot is a way to capture the far richer implant stream behind it. Curexo, which does not make implants, built CUVIS-joint to work with any implant brand and to drive the bone cut autonomously rather than guiding a surgeon's hand. Open and active, against closed and assisted. In price-sensitive emerging markets and hospitals that refuse to be married to one implant vendor, that is a real wedge — and a niche it shares with essentially only one other company.
Total liabilities of just ₩4.89bn against ₩101bn of assets — a current ratio above 2,000%. For a company this size, the cash is not a war chest waiting to be deployed; it is the reason the headline April-2026 financing makes no sense as financing.
Cumulative CUVIS-joint procedures — the meter on the installed base
~43,000
Across 100-odd hospitals in nine-plus countries, up from ~4,000 in 2022 and ~30,000 by mid-2025. The procedure count is the annuity base — though Curexo discloses no per-procedure consumable price, so its size is directional, not measured.
From distributor to surgeon's tool
Three years ago the company's center of gravity was distribution. In FY2023 the captive Trade segment — food raw materials sold almost entirely to affiliated beverage and noodle makers — was about 40% of revenue, the kind of low-margin ballast that keeps the lights on and signals nothing. By FY2025 the Medical Robot segment was 49% of revenue and the clear profit engine. The swing is violent in both directions: the robot segment collapsed in FY2024, losing ₩7.1bn at the operating line and dragging the whole group into the red, then rebounded the next year to a ₩1.28bn operating profit. The robots are now most of the revenue and most of the profit. The distributor has become a tool-maker.
A loss trough in FY2024, then the first clear profit in FY2025 as the Medical Robot segment turnsRevenue (bars) and operating margin (line). The dashed zero line shows how far below breakeven FY2024 fell (−10.5%) before FY2025 returned to a clear operating profit (+3.2%). Source: Curexo consolidated financials via DART, FY2023–FY2025 (rcept_no 20260317000027).
The product the whole thesis rests on. Curexo owns the software, the clearances and the brand for CUVIS-joint and CUVIS-spine — but no factory; the machines are built by Korean contract manufacturers. The fixed cost is research and a sales force, not plant.
The implant majors own the room
It is worth being honest about the size of the fight. Curexo's entire robot segment is about US$26m. Stryker's knee-and-hip franchise alone — the business its Mako fleet exists to feed — is measured in billions, on more than 3,000 installed systems. Curexo's hundred-odd hospitals are roughly 3% of that fleet. The UK's NICE, when it assessed orthopedic robots for the NHS, named Mako, ROSA, CORI and VELYS, plus China's SkyWalker. CUVIS-joint was not on the list. Curexo is not a scale peer to these companies and should not be read as one. Its game is a specific lane the majors under-serve, not a frontal assault on the implant oligopoly.
Platform
Maker
Installed base
Approach
Mako
Stryker
>3,000 systems
Closed, semi-active
ROSA
Zimmer Biomet
~2,000 systems
Closed, multi-anatomy
VELYS
J&J / DePuy
31 countries
Closed, CT-free
CUVIS-joint
Curexo
~43k procedures
Open, fully autonomous
SkyWalker
MicroPort
20+ countries
Increasingly open
Orthopedic surgical-robot platforms compared by installed base and architecture. Curexo's CUVIS-joint is placed in roughly 100 hospitals across nine-plus countries with ~43,000 cumulative procedures; the implant majors run closed platforms that lock hospitals into their own implants, while Curexo and (largely) MicroPort keep the platform open. Source: 03-competitors.md §2; installed-base figures are company / official releases.
Where the annuity is earned. Each placed system is meant to generate recurring consumable and service revenue case after case — but the per-procedure economics are not disclosed, which is exactly the number an acquirer would send a channel-check to find.
Global approvals as the throttle
Because the platform sells into one country at a time, growth is gated not by end-demand but by the regulatory calendar — every new geography is a separate clearance, and the FY2025–26 export surge is literally a sequence of approvals stacking up. The hip indication for CUVIS-joint cleared in Korea in October 2025, finally matching Mako's dual knee-and-hip capability. Japan's PMDA cleared the system in 2025, with Kyocera as the distribution partner; Europe's CE-MDR followed in 2026; and the company reports a US FDA clearance in March 2026 — a milestone worth flagging, because it is company-reported and not yet matched to an FDA database number. Each clearance opens a market the company could not legally sell into the day before. For a forecast, the thing to model is the approval cadence, not the market's growth rate.
April-2026 convertible bond — the governance tell, not a raise
₩0.5bn
Issued to three named orthopedic surgeons under a 'CUVIS-joint technology development' banner, at a premium conversion price with no refixing. Against ₩187bn of cash it funds nothing — it is a downside-protected option grant binding the doctors who specify the robots into the equity story. A conflict-of-interest flag in plain sight.
The installed base as an annuity — real, not yet durable
Here is the part to read slowly, because it is where the bull case and the skeptic meet. The model only works if the consumable-and-service stream on those 43,000 procedures grows into something that smooths the lumpy, order-driven business of selling whole systems. FY2025's robot-segment swing — from a ₩7.1bn operating loss to a ₩1.28bn profit — is the first visible evidence that the per-procedure economics exist. But it is one year, and the gloss is worth resisting. FY2025 robot revenue of ₩36.4bn barely cleared the FY2023 peak of ₩34.2bn: the company spent two years and a crisis in India — where its largest distributor reverse-engineered the product and launched a copy — getting roughly back to where it had been. And the recovery is already under pressure. Q1-2026 relapsed to an operating loss on revenue down 18% year on year. The annuity is real in direction; it is not yet durable in size.
The cash flow underlines the caution. Curexo reported a +₩2.4bn operating profit in FY2025, but operating cash flow was −₩11.3bn — the gap is working capital and inventory building up in a system-sale business, sitting on top of a −₩146bn accumulated deficit that four loss years and a deep FY2024 trough left behind. The accounting profit is real; it did not turn into cash. None of this breaks the thesis. It simply means the right verdict is the careful one: the pivot is genuine and the balance sheet can fund it without dilution, but the recurring-revenue flywheel that justifies the whole valuation is, at this scale, still being built.
“The convertible bond is the breadcrumb, not the loaf. A company holding ₩187bn in cash does not raise ₩0.5bn to fund a strategy. It hands paper to three surgeons because the people who decide which robot goes into the operating room are the demand side of an installed-base business — and Curexo just put them on the cap table.”
— Nathan Research Group, KOSDAQ Frontier Series N°04
The economics the majors keep and Curexo gives up. Stryker and Zimmer use the robot to lock in their own high-margin implants; Curexo, implant-agnostic by design, forgoes that richer stream and must earn its annuity on thinner consumables and service — the open platform's cost as well as its edge.
How to read a company like this
The lesson travels beyond one robot-maker. A pivot is easy to narrate and hard to prove, and the proof is rarely in the headline event — it is in whether the new economics actually convert to cash, and whether a single good year is a turn or a bounce. For Curexo specifically, the things to watch are not the next quarter's revenue, which will swing with the timing of large export orders, but two slower signals: whether the consumable-and-service mix rises as a share of robot revenue, and whether the open-platform wedge holds against a deep-pocketed Chinese rival in the exact emerging markets Curexo is winning. The cash buys it time, and the surgeons on the cap table tell you the company knows precisely where its demand comes from. Nathan Research Group has specialized in the Korean economy since 2013; the most revealing line in a turnaround's accounts is often the one that shows whether the new profit ever became cash.
Working With Nathan Research Group
Partner With Nathan Research Group
Public filings establish the shape of Curexo — the ₩187bn cash pile, the FY2025 turn to profit, the export surge, the convertible bond to three surgeons. What actually decides a deal — what a CUVIS-joint procedure really earns per case once the system is placed, how durable the open-platform wedge is against Stryker and a deep-pocketed MicroPort, whether the company-reported US FDA clearance is real, and how much of the China-built supply chain is exposed to FX — lives with the people who install, reimburse, and compete with these robots. Reaching them, compliantly, is what we do.
Korea’s first dedicated expert network — Seoul, since 2013
Who we put in the room
Surgical-robotics clinical lead
Arthroplasty surgeons who have run CUVIS-joint, Mako and ROSA in the OR — on accuracy, workflow, and whether autonomous cutting changes outcomes or just marketing.
Orthopedic surgeon / KOL (India)
India is the single most important export market. Surgeons in the Meril and Biorad networks read real adoption, the MISSO copycat fallout, and how sticky an installed robot truly is.
Robotic-surgery coverage is uneven by geography. Reimbursement specialists pressure-test whether each new clearance actually converts into paid procedures.
Surgical-robot market structure (open vs closed; THINK Surgical)
The open-platform niche is shared with THINK Surgical — Curexo's distributor in the US and EU and its competitor everywhere else. Insiders read that frenemy dependency.
Capital allocation & financial diligence
The −₩11.3bn operating cash flow against a +₩2.4bn profit, the −₩146bn accumulated deficit, and the KOL convertible-bond governance flag — earnings quality, not the headline.
Asian med-device manufacturing & supply chain
Curexo owns no factories; the robots are built by Korean contract makers and sold abroad. Operators read FX, OEM capacity, and component-supply risk in an asset-light model.
How an engagement works
1Scope
We turn your thesis into a precise expert profile and question set, mapped to the decisions you need to close.
2Source & vet
We screen and compliance-clear each expert — relevance, recency, and the absence of conflicts — before any call.
3Convene & synthesize
We arrange interviews on your timeline and, where useful, deliver written synthesis tied back to your questions.
If your team is evaluating Curexo, the surgical-robotics market, or the broader medical-device sector, tell us the decision you’re trying to make.
A direct reply from a partner, not an intake form.
Based solely on public sources. Nathan Research Group does not request or facilitate material non-public information, and runs every engagement through a documented compliance protocol.
